Shots:

• AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally- Molecular Partners will reacquire the development and commercial rights of abicipar globally
• Molecular Partners will put a special committee to assess the program & figure out the next steps. Additionally- the companies will continue the ongoing discovery collaboration to evaluate additional DARPin candidates for other ophthalmic indications
• Abicipar is a long-acting anti-VEGF DARPin molecule which is being evaluated in two P-III studies i.e.- CEDAR and SEQUOIA that supported the non-inferior efficacy of Abicipar (quarterly dosing regimen) to maintain vision gains

  | Ref: Molecular Partners | Image: Swiss Biotech Association